HighTower Advisors
LXRX icon

HighTower Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

HighTower Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,910
Closed -$14.1K – 3963
2025
Q2 		$14.1K Buy
+14,910
New +$9.66K ﹤0.01% 3625
2021
Q2 		– Sell
-10,903
Closed -$64K – 3289
2021
Q1 		$64K Buy
+10,903
New +$75.5K ﹤0.01% 2802

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's LXRX Position: Q3 2025 in Review

HighTower Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2025, closing a stake of 14,910 shares — an estimated $14.1K sold.

HighTower Advisors first reported a position in LXRX in Q1 2021 and held it in 2 quarters. The position peaked at $64K in Q1 2021. 123 funds tracked by Wall St. Rank hold LXRX as of Q3 2025.

  • HighTower Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • HighTower Advisors sold 14,910 Lexicon Pharmaceuticals shares in Q3 2025, an estimated $14.1K.
  • HighTower Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • HighTower Advisors's Lexicon Pharmaceuticals position peaked at $64K in Q1 2021.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2025.

Based on HighTower Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.